These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31081451)

  • 21. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018.
    Moradi N; Sharmin S; Malpas C; Ozakbas S; Shaygannejad V; Terzi M; Boz C; Yamout B; Turkoglu R; Karabudak R; Hamdy S; Soysal A; Altıntaş A; Inshasi J; Al-Harbi T; Alroughani R; Kalincik T;
    CNS Drugs; 2021 Oct; 35(10):1097-1106. PubMed ID: 34164782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
    J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of the 10-year direct costs for treating multiple sclerosis.
    Moccia M; Palladino R; Lanzillo R; Triassi M; Brescia Morra V
    Acta Neurol Scand; 2017 May; 135(5):522-528. PubMed ID: 27357245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
    Zivadinov R; Cookfair DL; Krupp L; Miller AE; Lava N; Coyle PK; Goodman AD; Jubelt B; Lenihan M; Herbert J; Gottesman M; Snyder DH; Apatoff BR; Teter BE; Perel AB; Munschauer F; Weinstock-Guttman B
    BMC Neurol; 2016 Jul; 16():102. PubMed ID: 27416843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
    Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in prognosis of the Danish multiple sclerosis population over time.
    Magyari M; Joensen H; Kopp TI; Pontieri L; Koch-Henriksen N
    Mult Scler; 2022 Dec; 28(14):2190-2201. PubMed ID: 35822309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
    Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
    Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
    Roos I; Leray E; Frascoli F; Casey R; Brown JWL; Horakova D; Havrdova EK; Trojano M; Patti F; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Prat A; Girard M; Grammond P; Sola P; Ferraro D; Ozakbas S; Bergamaschi R; Sá MJ; Cartechini E; Boz C; Granella F; Hupperts R; Terzi M; Lechner-Scott J; Spitaleri D; Van Pesch V; Soysal A; Olascoaga J; Prevost J; Aguera-Morales E; Slee M; Csepany T; Turkoglu R; Sidhom Y; Gouider R; Van Wijmeersch B; McCombe P; Macdonell R; Coles A; Malpas CB; Butzkueven H; Vukusic S; Kalincik T; ;
    Brain; 2020 Sep; 143(9):2742-2756. PubMed ID: 32947619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.